Global Cancer Technology

Early Stage

GCT’s lead cancer technology is its remote-controlled cancer drug delivery platform.

Analytics

Raised to Date: Raised: $24,400

Aggregate Commitments $

Platform

Dalmore Group

Start Date

09/08/2020

Close Date

09/08/2021

Min. Goal

$500

Max. Goal

$7,000,000

Min. Investment

$500

Security Type

Equity - Common

Funding Type

RegA+

Price Per Share

$2.00

Rolling Commitments $

Status
Funded
Reporting Date

09/30/2021

Days Remaining
Funded
% of Min. Goal

4,880%

% of Max. Goal

0%

Likelihood of Max
Funded
Avg. Daily Raise

$67

Momentum
Funded
Log in or create a free account today to gain access to KingsCrowd analytics.
Location

San Diego, California

Industry

Healthcare & Pharmaceuticals

Tech Sector

HealthTech

Global Cancer Technology is raising funds on Dalmore Group through Reg A+ crowdfunding. The company has acquired multiple patented technologies currently being tested as novel treatments for deadly diseases. The technology is presently focused on detecting and treating brain cancer and includes scintillating nanoparticles, cancer biomarkers, and cancer inhibitors. Global Cancer Technology is working with world-renowned scientists of the Barrow Neurological Institute, Baylor Scott & White Hospital, and the University of California San Diego. John P. Clark founded Global Cancer Technology in May 2017. The current crowdfunding campaign has no minimum target and a maximum target of $7,000,000. The campaign proceeds will be used for new product development, working capital, and general corporate purposes.

Balance Sheet

Cash and Cash Equivalents

$70,706

Investment Securities

$0

Total Investments

$0

Accounts and Notes Receivable

$0

Loans

$0

Property, Plant and Equipment (PP&E)

$175

Property and Equipment

$0

Total Assets

$320,881

Accounts Payable & Accrued Liabilities

$153,923

Policy Liabilities and Accruals

$0

Deposits

$0

Long Term Debt

$0

Total Liabilities

$383,035

Total Stockholders' Equity

$-62,154

Total Liabilities and Equity

$320,881

Statement of Comprehensive Income Information

Total Revenues

$0

Total Interest Income

$0

Costs & Expenses Applicable to Rev

$0

Total Interest Expenses

$0

Depreciation and Amortization

$174

Net Income

$-140,421

Earnings Per Share - Basic

$0

Earnings Per Share - Diluted

$0

Auditor: Ankit Consulting Inc.
Financials as of: 09/08/2020
Log in or create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
Global Cancer Technology 04/29/2022 Netcapital $26,682,636 $0 Equity - Common Not Funded RegCF
Global Cancer Technology 09/08/2021 Dalmore Group - $24,400 Equity - Common Funded RegA+
Global Cancer Technology 02/25/2020 Netcapital $11,571,400 $107,000 Equity - Common Funded RegCF
Log in or create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Starter

$8.33 /month
billed annually
Free portfolio tracking. Limited reports and filters.
Plan Includes:
Everything in Free, plus
Advanced company search ( limited filters)
Founder profiles and exclusive webinars
2 Analyst Reports per month
Get Starter Annual

Pro

$25 /month
billed annually
Unlimited analyst reports and market analytics.
Plan Includes:
Everything in Starter, plus
Full access to all Analyst Reports
Filter on Analyst Reports (e.g. Top Deal, Deal to Watch, etc.)
Market Analytics
Get Pro Annual

Merlin

$41.67 /month
billed annually
Full site access including KingsCrowd ratings.
Plan Includes:
Everything in Pro, plus
Search and filter companies by KingsCrowd ratings
Company specific KingsCrowd rating and risk assessment
Get Merlin Annual
Already a member? Log in here.

Create your first portfolio

Create your very own investment portfolio on KingsCrowd.

Now you can track all of your startup investments in one place utilizing our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
Global Cancer Technology on Dalmore Group 2021
$
Platform: Dalmore Group
Security Type: Equity - Common
Invest in a different round for this company? Use my investment date to determine which raise I invested in.

Follow company

Follow Global Cancer Technology on Dalmore Group 2021
View on Dalmore Group (Closed)
Bullish / Bearish
You're Bullish on Global Cancer Technology on Dalmore Group 2021

Thank you for your vote on Global Cancer Technology on Dalmore Group 2021

Bullish / Bearish
You're Bearish on Global Cancer Technology on Dalmore Group 2021

Thank you for your vote on Global Cancer Technology on Dalmore Group 2021